Ibandronate
- Generic Name
- Ibandronate
- Brand Names
- Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H23NO7P2
- CAS Number
- 114084-78-5
- Unique Ingredient Identifier
- UMD7G2653W
- Background
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.
Ibandronate was granted FDA approval on 16 May 2003.
- Indication
For the treatment and prevention of osteoporosis in postmenopausal women.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
- Conditions
- PainNeoplasm MetastasisBone Neoplasm
- Interventions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 163
- Registration Number
- NCT00099203
Study of Investigational Drug in Osteoporosis (MK-0217-908)
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 203
- Registration Number
- NCT00092053
Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain
- Conditions
- Metastatic CancerPainProstate Cancer
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 580
- Registration Number
- NCT00082927
- Locations
- 🇬🇧
Cancer Care Centre at York Hospital, York, England, United Kingdom
🇬🇧Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom
🇬🇧West Cumberland Hospital, Whitehaven, England, United Kingdom
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
- Conditions
- Post-Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2004-04-21
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 719
- Registration Number
- NCT00081653
MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1609
- Registration Number
- NCT00048061
DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1395
- Registration Number
- NCT00048074
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.